✉ Email this page to a colleague
« Back to Dashboard
Iniparib is an investigational drug.
There have been 21 clinical trials for Iniparib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Carcinoma, Ovarian Epithelial. The leading clinical trial sponsors are Sanofi, Cantargia AB, and BiPar Sciences.
Recent Clinical Trials for Iniparib
|Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.||Spanish Breast Cancer Research Group||Phase 1/Phase 2|
|Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.||Cantargia AB||Phase 1/Phase 2|
|Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial||Sanofi||Phase 3|